Full programme

View the entire programme below, or: 

Click here to view abstracts (restricted access) and the list of e-posters



Wednesday, April 24th 2019

SCOPE (Skin Care in Organ Transplant Patients, Europe) Meeting

Wednesday, April 24th 2019 | 09:00 - 12:30 | PETIT AMPHITHEATRE - Level 0

Chair : Deniz SECKIN (Turkey)

  • Welcome and introduction
    Deniz SECKIN (Turkey)
  • Melanoma in the context of organ transplantation: current issues and future outlooks
    Christoph HOELLER (Austria), Alexandra GEUSAU (Austria)
  • Challenges for immunotherapy of Merkel cell carcinoma in organ transplant patients (including Q&A)
    Jurgen BECKER (Germany)
  • Posttransplant Merkel cell carcinoma: what are the challenges and what does the SCOPE experience tell us?
    Carla FERRÁNDIZ-PULIDO (Spain)
  • Tumor board: Case 1, Case 2 and Case 3
  • Coffee break
  • Management of the posttransplant advanced and high-stage cutaneous SCC: What are the difficulties, challenges and solutions? (including Q&A)
    Chrysalyne SCHMULTS (United States)
  • Closing remarks and future perspectives
    Charlotte PROBY (United Kingdom)

Controversies in Dermato-oncology 1

Wednesday, April 24th 2019 | 13:30 - 14:45 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Céleste LEBBE (France), Claus GARBE (Germany), Jean-Jacques GROB (France)

  • Prevention campaign will prevent skin cancer - Yes
    Alexander STRATIGOS (Greece)
  • Prevention campaign will prevent skin cancer - No
    Claus GARBE (Germany)
  • Will lymph node surgery remain a main therapy in melanoma? - Yes
    David MORENO-RAMIREZ (Spain)
  • Will lymph node surgery remain a main therapy in melanoma? - No
    Axel HAUSCHILD (Germany)
  • Adjuvant therapy should be moved to primary melanoma stage II - Yes
    Jean-Jacques GROB (France)
  • Adjuvant therapy should be moved to primary melanoma stage II - No
    Paul LORIGAN (United Kingdom)

Controversies in Dermato-oncology 2

Wednesday, April 24th 2019 | 14:45 - 16:00 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Brigitte DRENO (France), Ketty PERIS (Italy), Alexander STRATIGOS (Greece)

  • We should routinely measure quality of life of advanced melanoma patients - Yes
    Jessica HASSEL (Germany)
  • We should routinely measure quality of life of advanced melanoma patients - No
    Isabelle BORGET (France)
  • Tumor mutational burden (TMB) will guide our future systemic treatments - Yes
    Selma UGUREL (Germany)
  • Tumor mutational burden (TMB) will guide our future systemic treatments - No
    Olivier MICHIELIN (Switzerland)
  • Treatment of advanced melanoma: combining or sequencing? - Combining
    Céleste LEBBE (France)
  • Treatment of advanced melanoma: combining or sequencing? - Sequencing
    Dirk SCHADENDORF (Germany)

Opening Ceremony

Wednesday, April 24th 2019 | 17:30 - 18:00 | AMPHITHEATRE LAVOISIER - Level 1

  • Welcome address
    Céleste LEBBE (France), Claus GARBE (Germany)
  • New developments in occupational skin cancer: WHO disease burden project and implications for our patients
    Swen Malte JOHN (Germany)

Keynote lectures 1

Wednesday, April 24th 2019 | 18:00 - 19:00 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Céleste LEBBE (France), Claus GARBE (Germany), Caroline ROBERT (France)

  • The long journey from melanocyte to melanoma
    Boris BASTIAN (United States)
  • Targeting innate immunity in cancer treatment
    Eric VIVIER (France)
  • Raising the efficacy in immunotherapy of melanoma: what are we going to achieve?
    Beth HELMINK (United States)
Thursday, April 25th 2019

Management of advanced melanoma

Thursday, April 25th 2019 | 08:30 - 09:30 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Paolo ASCIERTO (Italy), Thomas GAJEWSKI (United States), Caroline ROBERT (France)

  • Combining or sequencing targeted therapy and immunotherapy
    Paolo ASCIERTO (Italy)
  • How to overcome primary and secondary resistance to immune checkpoint inhibitor
    Thomas GAJEWSKI (United States)
  • How should we evaluate our patients in the era of immunotherapy? irRECIST, irRC, iRECIST?
    Michael MAJER (France)

Rare skin cancers and borderline neoplasms such as MELTUMP, clinic-pathological approach

Thursday, April 25th 2019 | 08:30 - 10:30 | PETIT AMPHITHEATRE - Level 0

Chair : Petr ARENBERGER (Czech Republic), Boris BASTIAN (United States), Maxime BATTISTELLA (France), Matilda BYLAITE-BUCINSKIENE (Lithuania), Arnaud DE LA FOUCHARDIERE (France), Judit OLAH (Hungary)

  • Adnexal Tumors
    Maxime BATTISTELLA (France)
    Arnaud DE LA FOUCHARDIERE (France)
  • Neoplastic disorders of the nipple
    Erika VARGA (Hungary)
  • Borderline vascular tumors
    Matilda BYLAITE-BUCINSKIENE (Lithuania)
  • Soft tissue tumors
    Judit OLAH (Hungary)
  • Overview on rare skin tumors
    Petr ARENBERGER (Czech Republic)


Thursday, April 25th 2019 | 09:00 - 10:30 | ROOM 151 - Level 1

Chair : Martine BAGOT (France), Julia SCARISBRICK (United Kingdom), Rudolf STADLER (Germany)

  • Tumor clone frequency is a robust predictor of progression and survival in patients with early stage mycosis fungoides
    Adèle DE MASSON (France)
  • International landscape of therapies in CTCL, Results of the PROCLIPI Study
    Pietro QUAGLINO (Italy)
  • Therapeutic Strategies for improved management in CTCL
    Rudolf STADLER (Germany)
  • New monoclonal antibodies for the treatment of CTCL
    Martine BAGOT (France)
  • Clinical endpoints updates and considerations for future staging
    Julia SCARISBRICK (United Kingdom)
  • Management of Cutaneous B cell lymphoma
    Antonio COZZIO (Switzerland)

How to prevent Melanoma Progression in tumor-free patients of…

Thursday, April 25th 2019 | 09:30 - 10:30 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Axel HAUSCHILD (Germany), Jean-Jacques GROB (France), Nicolas MEYER (France)

  • Stage II
    Jean-Jacques GROB (France)
  • Stage III
    Axel HAUSCHILD (Germany)
  • Stage IV
    Nicolas MEYER (France)

Trends in skin cancer epidemiology

Thursday, April 25th 2019 | 11:00 - 12:00 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Sara GANDINI (Italy), Claus GARBE (Germany), David WHITEMAN (Australia)

  • Incidence of melanoma in Europe 1950 - 2030
    Claus GARBE (Germany)
  • Which percentage of melanoma is caused by UV radiation, and what proportion could be prevented?
    David WHITEMAN (Australia)
  • Nevi and melanoma: who, when and how?
    Sara GANDINI (Italy)
  • What do we achieve with screening examinations?
    Andreas STANG (Germany)

Biomarkers in melanoma

Thursday, April 25th 2019 | 11:00 - 12:00 | PETIT AMPHITHEATRE - Level 0

Chair : John HAANEN (Netherlands), Olivier MICHIELIN (Switzerland), Selma UGUREL (Germany)

  • Biomarkers in melanoma, an overview
    Olivier MICHIELIN (Switzerland)
  • Circulating cytokines and immune related toxicity
    Jenny LEE (Austria)
  • Microbiome
    Beth HELMINK (United States)
  • Single cell RNA seq of immune infiltrates
    Krisztian HOMICSKO (Switzerland)

Cases of adverse events in immuno-oncology

Thursday, April 25th 2019 | 11:00 - 12:00 | ROOM 151 - Level 1

Chair : Barouyr BAROUDJIAN (France), Lucie HEINZERLING (Germany), Christoph HOELLER (Austria)

  • A case of Myositis
    Lucie HEINZERLING (Germany)
  • Myocarditis: what clinicians should know
    Dimitri ARANGALAGE (France)
  • An unusual Hematologic side effect
    Erwin STRASSER (Germany)
  • Immune related hepatitis: can we resume the treatment ?
    Olivier ROUX (France)
  • Beware of rare endocrinologic immune related adverse events
    Florence BRUNET-POSSENTI (France)

Keynote lectures 2

Thursday, April 25th 2019 | 12:00 - 13:00 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Céleste LEBBE (France), Alexander STRATIGOS (Greece)

  • Where and when will melanoma incidence decrease?
    David WHITEMAN (Australia)
  • How to modulate tumor microenvironment?
    Thomas GAJEWSKI (United States)
  • Molecular resistance to targeted therapy, from bench to bedside
    Grant MCARTHUR (Australia)

Prevention and skin cancer screening

Thursday, April 25th 2019 | 14:00 - 15:00 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Véronique DEL MARMOL (Belgium), Ana Maria FORSEA (Romania), Eduardo NAGORE (Spain)

  • UVR and cellular damage: implications for skin cancer prevention
    Amaya VIROS (United Kingdom)
  • Melanoma risk and sunbeds use – time to close the debate
    Mariano SUPPA (Belgium)
  • Prevention according to different clinical profile
    Eduardo NAGORE (Spain)
  • Skin cancer Chemoprevention - current evidence
    Ana Maria FORSEA (Romania)

Actinic keratosis and field cancerisation

Thursday, April 25th 2019 | 14:00 - 15:00 | ROOM 151 - Level 1

Chair : Ketty PERIS (Italy), Eggert STOCKFLETH (Germany), Nicole KELLENERS-SMEETS (Netherlands)

  • Biology of AK
    Eggert STOCKFLETH (Germany)
  • Diagnosis of AK
    Caterina LONGO (Italy)
  • Field directed treatments
    Nicole KELLENERS-SMEETS (Netherlands)
  • AK treatment in organ transplant recipients
    Ketty PERIS (Italy)

Free communications 1: Melanoma treatment

Thursday, April 25th 2019 | 14:00 - 15:00 | PETIT AMPHITHEATRE - Level 0

Chair : Sophie DALAC-RAT (France), Lionel LARUE (France), Charlotte PROBY (United Kingdom), Dimitris SGOUROS (Greece), Damien GIACCHERO (France)

  • FC02 - Safety & efficacy of cryopreserved autologous tumor infiltrating lymphocytes (LN-144, lifileucel) in previously treated metastatic melanoma patients
    A Sarnaik, S S Thomas, D Davar, J M Kirkwood, H Kluger, J Lutzky, A C Pavlick, B Curti, E Whitman, O Hamid, M Ernstoff, G Q Phan, P Corrie, J Chesney, S Suzuki, D Barton, M Fardis, H-T Arkenau* (United States)
  • FC03 - Response rates with talimogene laherparepvec monotherapy in patients with stage IIIB–IVM1C melanoma previously treated with a checkpoint inhibitor
    Helen Gogas, Ralf Gutzmer, Josep Malvehy, Janice M Mehnert, Chunxu Liu, Cheryl Pickett, Wendy Snyder, Jason Chesney (Greece)
  • FC04 - Redirected T-cell mediated lysis in patients with metastatic uveal melanoma with gp100-directed TCR IMCgp100: overall survival findings
    Takami Sato, Paul D Nathan, Leonel Hernandez-Aya, Joseph J Sacco, Marlana Orloff, Frank Engler, Nicola Little, Rachael Easton, Richard D Carvajal (United States)
  • FC06 - Prediction of irAEs in ipilimumab-treated melanoma patients based on serum autoantibodies
    Jessica Cecile Hassel, Joanna Mangana, Reinhard Dummer, Claudia Pföhler, Kilian Wistuba-Hamprecht, Benjamin Weide, Lara Hakim-Meibodi, Friedegund Meier, Jasmin Roth, Hans-Dieter Zucht, Peter Schulz-Knappe, Petra Budde (Germany)
  • FC07 - Update of survival and cost of metastatic melanoma with new drugs: estimations from the melbase cohort
    Marguerite Kandel, Clara Allayous, Stéphane Dalle, Laurent Mortier, Sophie Dalac, Caroline Dutriaux, Marie-Thérèse Leccia, Federico Rotolo, Bernard Guillot, Philippe Saiag, Jean-Philippe Lacour, Delphine Legoupil, Thierry Lesimple, François Aubin, Marie Beylot-Barry, Vincent Descamps, Jean-Philippe Arnault, Florence Granel-Brocard, Pierre-Emmanuel Stoebner, Alain Dupuy, Eve Maubec, Jean-Jacques Grob, Stefan Michiels, Celeste Lebbe, Isabelle Borget (France)
  • FC08 - Tace for patients with metastatic melanoma in the liver
    Dmitry Martynkov, Vladislav Kosyrev, Valeria Nazarova (Russian Federation)
  • FC05 - Real world evidence in advanced melanoma from a national, non-interventional study of nivolumab monotherapy or in combination with ipilimumab (nico)
    R. Gutzmer, T. Eigentler, P. Mohr, D. Göppner, S. Haferkamp, M. Herber, R. Herbst, F. Meier, F. Meiss, C. Pföhler, S. W. Schneider, P. Terheyden, J. Ulrich, J. Utikal, M. Weichenthal, C. Weishaupt, J. Welzel, D. Schadendorf (Germany)
  • FC01 - Real-world evidence of the effectiveness of cobimetinib combined with vemurafenib in patients with BRAF V600 mutation-positive advanced melanoma
    Nicolas Meyer, David Pérol, Anne-Bénédicte Duval-Modeste, Adrian Gorana, Laila El Adaoui, Yoann Lelarge, Ralph Niarra, Christine Mateus (France)

Non-surgical local tumor treatment: act locally, but think distant

Thursday, April 25th 2019 | 16:30 - 18:00 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Christoph HOELLER (Austria), Ricardo VIEIRA (Portugal), Philippe SAIAG (France)

  • Radiotherapy
    Philippe SAIAG (France)
  • Intralesional injections
    Christoph HOELLER (Austria)
  • Other local treatments
    Ricardo VIEIRA (Portugal)

Brain metastases

Thursday, April 25th 2019 | 16:30 - 18:00 | ROOM 151 - Level 1

Chair : Emilie LE RHUN (France), Friedegund MEIER (Germany), Hussein TAWBI (United States)

  • Diagnosis and local treatment of CNS metastasis: surgery and radiotherapy
    Michael WELLER (Switzerland)
  • Targeted therapy alone or in combination with RT in melanoma CNS metastases
    Friedegund MEIER (Germany)
  • Immunotherapy alone or in combination with RT in melanoma CNS metastases
    Hussein TAWBI (United States)
  • Challenges in the design of CNS metastases trials
    Emilie LE RHUN (France)

Free communications 2: Carcinoma

Thursday, April 25th 2019 | 16:30 - 18:00 | PETIT AMPHITHEATRE - Level 0

Chair : Stéphane DALLE (France), Helen GOGAS (Greece), Janice MEHNERT (United States)

  • FC09 - Follow-up of patients with complete remission of locally advanced basal-cell carcinoma after vismodegib discontinuation: french study of 119 patients
    Florian Herms, Jerome Lambert, Jean-Jacques Grob, Luc Haudebourg, Martine Bagot, Sophie Dalac (France)
  • FC17 - Prognostic subgroups in stage T3-AJCC8 for cutaneous squamous cell carcinoma: tentative T3 stage subclassification
    Alberto Conde-Ferreirós, Luis Antonio Corchete-Sánchez, Laura Puebla-Tornero, Concepción Román-Curto, Javier Cañueto (Spain)
  • FC11 - Cemiplimab in patients with advanced cutaneous squamous cell carcinoma: clinical experience from the phase 1 and phase 2 studies
    Michael R Migden, Alexander Guminski, Karl D Lewis, Dirk Schadendorf, Nikhil I Khushalani, Axel Hauschild, Kyriakos P Papadopoulos, Yamini Patel, Michael Andria, Matthew G Fury, Danny Rischin, Chrysalyne D Schmults (United States)
  • FC10 - Cemiplimab for the treatment of metastatic and locally advanced cutaneous squamous cell carcinoma: prospective study in a french onco-dermatology unit
    Florian Herms, Julie Delyon, Barouyr Baroudjian, Adele De Masson, Celeste Lebbe (France)
  • FC15 - Opportunities for improving the efficiency of keratinocyte cancer care in primary and specialist care: population-based dutch cohort studies
    Marlies Wakkee, Sven van Egmond, Patrick Bindels, Johan van der Lei, Marieke Louwman, Tamar Nijsten, Loes Hollestein (Netherlands)
  • FC12 - Synergistic targeting of PI3K-MTOR and MAPK pathwas in Merkel cell carcinoma
    Arturo Temblador, Dimitrios Topalis, Graciela Andrei, Robert Snoeck (Belgium)
  • FC13 - Phase II study of KX2-391 ointment 1%, a novel field treatment based on src/tubulin polymerisation inhibition, for actinic keratosis
    Michael Jarratt, Steven Kempers, Seth Forman, David Cutler, Hui Wang, Jane Fang, Rudolf Kwan (United States)
  • FC14 - Long-term clinical benefit to anti-CCR4 mogamulizumab: post-hoc results from mavoric, a phase 3 study in previously treated cutaneous t-cell lymphoma
    Martine Bagot, Stephane Dalle, Lubomir Sokol, Athanasios Tsianakas, Amy Musiek, Pablo L. Ortiz-Romero, Brian Poligone, Madeline Duvic, Craig Elmets, Mollie Leoni, Karen Dwyer
  • FC16 - Outcome after treatment for sebaceous carcinoma: a multicenter study
    Eva Huis In 'T Veld, Nicoline Post, Ronald Keizer, Jeroen Versteeg, Nicoline Naus, Germaine Relyveld, Myles Smith, Alexander van Akkooi, Dirk Grunhagen, Dirk Strauss, Cornelis Verhoef
  • FC18 - Trends in knowledge, attitude and behavior about sun-protection in 15-75 aged french people: baromètre cancer, 2005-2010-2015
    Anne Thuret, Colette Ménard, Christophe Léon, Jean-Baptiste Richard, Christine Jestin, Florence de Maria (France)
  • FC19 - Trends of sunbed use and in characteristics, knowledge, attitude and behavior in 15-75 aged french sunbed users: baromètre cancer, 2010-2015
    Anne Thuret, Colette Ménard, Christophe Léon, Jean-Baptiste Richard, Christine Jestin, Florence de Maria (France)
Friday, April 26th 2019

Neoadjuvant therapy

Friday, April 26th 2019 | 08:30 - 09:30 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Christian BLANK (Netherlands), James LARKIN (United Kingdom), Peter MOHR (Germany)

  • Neoadjuvant immunotherapy in melanoma
    Christian BLANK (Netherlands)
  • Neoadjuvant targeted therapy in melanoma
    Peter MOHR (Germany)
  • Neoadjuvant therapy and lessons from other tumor types and lessons to learn from former neoadjuvant trials in melanoma
    James LARKIN (United Kingdom)

Dermoscopy and confocal microscopy

Friday, April 26th 2019 | 08:30 - 09:30 | ROOM 151 - Level 1

Chair : Luc THOMAS (France), Iris ZALAUDEK (Austria), Caterina LONGO (Italy)

  • How dermoscopy improves differential diagnosis of melanoma
    Luc THOMAS (France)
  • How confocal microscopy improves management decisions
    Caterina LONGO (Italy)
  • When instruments are not enough, clinical clues are needed
    Aimilios LALLAS (Greece)
  • Questions & Answers

Developing a skin cancer center: what do we additionally achieve?

Friday, April 26th 2019 | 08:30 - 10:30 | PETIT AMPHITHEATRE - Level 0

Chair : Claus GARBE (Germany), Lidija KANDOLF-SEKULOVIC (Serbia and Montenegro), Dirk SCHADENDORF (Germany), Lise BOUSSEMART (France)

  • The optimal melanoma care pathway - the European perspective
    Lidija KANDOLF-SEKULOVIC (Serbia and Montenegro)
  • The system of quality assurance of skin cancer centers in Germany
    Claus GARBE (Germany)
  • Biobanking in skin cancer centers
    Dirk SCHADENDORF (Germany)
  • Translational research in a skin cancer center: when advances in next generation sequencing serve melanoma patients' care
    Lise BOUSSEMART (France)
  • E-health data and their role in skin cancer patient management
    Stine LUTZE (Germany)
  • Discussion

Practical tips for your surgical work

Friday, April 26th 2019 | 09:30 - 10:30 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Florence CORGIBET (France), Roland KAUFMANN (Germany), Vernon SONDAK (United States)

  • Before and after surgical procedures
    Florence CORGIBET (France)
  • Surgical procedures for the primary tumour
    Roland KAUFMANN (Germany)
  • About the sentinel node biopsies and nodal dissections
    Vernon SONDAK (United States)

New technologies for the diagnosis of skin cancer: from computer vision (automatized diagnosis) to innovation in photonics

Friday, April 26th 2019 | 09:30 - 10:30 | ROOM 151 - Level 1

Chair : Véronique DEL MARMOL (Belgium), Josep MALVEHY (Spain), Nesrine BRAHIMI (France)

  • High definition Ultrasound and skin cancer diagnosis approach
    Philippe BAHADORAN (France)
  • LC OCT : A new definition for Optical coherence tomography to diagnose skin cancer
    Mariano SUPPA (Belgium)
  • Early skin cancer detection and follow up using polarized dynamic speckle
    Xavier ORLIK (France)
  • Ex vivo confocal microscopy a new approach for skin cancer margins  
    Josep MALVEHY (Spain)

Management of advanced BCC and SCC

Friday, April 26th 2019 | 10:30 - 12:00 | PETIT AMPHITHEATRE - Level 0

Chair : Nicole BASSET-SEGUIN (France), Ulrike LEITER (Germany), Michael MIGDEN (United States)

  • General principles of management of NMSC
    Alexander STRATIGOS (Greece)
  • Surgery in advanced tumors (SCC and BCC)
    David MORENO-RAMIREZ (Spain)
  • Systemic treatment of advanced BCC
    Nicole BASSET-SEGUIN (France)
  • Systemic Treatment of advanced SCC
    Ulrike LEITER (Germany)
  • Expert Panel discussion
    David MORENO-RAMIREZ (Spain), Nicole BASSET-SEGUIN (France), Ulrike LEITER (Germany), Alexander STRATIGOS (Greece)
  • Expert panel discussion: Difficult to treat BCC- challenging cases
    Matilda BYLAITE-BUCINSKIENE (Lithuania)
  • Expert panel discussion: Difficult to treat SCC- challenging cases
    Michael MIGDEN (United States)

New therapeutic targets in melanoma

Friday, April 26th 2019 | 11:00 - 12:00 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Brigitte DRENO (France), Grant MCARTHUR (Australia), Jessica HASSEL (Germany)

  • Targeted therapies in BRAF mutated advanced melanoma: beyond BRAF and MEK combinations
    Grant MCARTHUR (Australia)
  • Targeted therapies in NRAS mutated melanoma, what can we expect ?
    Amelie BOESPFLUG
  • The future of immuno combination therapies in advanced melanoma
    Brigitte DRENO (France)
  • cKIT: still a relevant target?
    Julie DELYON (France)

Update on the skin cancers in immunosuppressed patients, on behalf of SCOPE

Friday, April 26th 2019 | 11:00 - 12:00 | ROOM 151 - Level 1

Chair : Emilie DUCROUX (France), Catherine HARWOOD (United Kingdom), Deniz SECKIN (Turkey)

  • Introduction
    Deniz SECKIN (Turkey)
  • What is new in the pathogenesis and treatment of posttransplant Kaposi's sarcoma?
    Stéphane BARETE (France)
  • The role and therapeutic implications of HPV presence in posttransplant squamous cell carcinoma: SCOPE research update
    Jan Nico BOUWES-BAVINCK (Netherlands)
  • Skin field cancerization: Converging transcription/ epigenetic regulatory pathways of translational value
    Paolo DOTTO (Switzerland)

Keynote lectures 3

Friday, April 26th 2019 | 12:00 - 13:00 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Céleste LEBBE (France), Jurgen BECKER (Germany)

  • Biology and therapy of Merkel cell carcinoma
    Paul NGHIEM (United States)
  • Targeting pathways in basal cell carcinoma: sonic hedgehog and beyond
    Nicole BASSET-SEGUIN (France)

What is new in melanoma biology?

Friday, April 26th 2019 | 14:00 - 15:30 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Boris BASTIAN (United States), Nicolas DUMAZ (France), Amaya VIROS (United Kingdom)

  • Nongenetic mechanisms as drivers of tumor evolution and therapy resistance
    Jean-Christophe MARINE (Belgium)
  • TERT promoter mutations, telomere length and melanoma survival and risk
    Rajive KUMAR (Germany)
  • Novel roles of ROCK-Myosin II in melanoma
    Victoria SANZ-MORENO (United Kingdom)
  • Neural Crest Stemness in Melanoma
    Lukas SOMMER (Switzerland)

Virus induced cancer

Friday, April 26th 2019 | 14:00 - 15:30 | ROOM 151 - Level 1

Chair : Jurgen BECKER (Germany), Nicolas DUPIN (France), Paul NGHIEM (United States)

  • Immunobiology of Merkel cell carcinoma
    Jurgen BECKER (Germany)
  • Progress and challenges in Merkel cell carcinoma management
    Paul NGHIEM (United States)
  • Update on oncogenesis and therapy for Kaposi’s sarcoma
    Nicolas DUPIN (France)

Best posters session

Friday, April 26th 2019 | 14:00 - 15:30 | PETIT AMPHITHEATRE - Level 0

Chair : Ralf GUTZMER (Germany), Gaëlle QUEREUX (France), Henri MONTAUDIE (France), Emmanuella GUENOVA (Switzerland)

  • P003 - Usefulness of the “two-step method” of digital follow-up in early stage melanoma detection in at high risk french patients - a retrospective study
    Giulia Gasparini, Nika Madjlessi, Julie Delyon, Luca Carmisciano, Nesrine Brahimi, Martine Bagot, Nicole Basset-Seguin, Maxime Battistella, Céleste Lebbé, Florian Herms, Barouyr Baroudjian (Italy)
  • P004 - Association between breslow thickness and dermoscopic findings in melanoma
    Maria Victoria Rodriguez Kowalczuk, Maria Manuela Martinez Piva, Aldana Vacas, Florencia Gallo, Rosa Marigle Rodrigues Vasconcelos, Maite Lisa Eliceche, Alicia Maria Kowalczuk, Luis Mazzuoccolo (Argentina)
  • P018 - A study on confidence in classification of skin lesions by deep neural networks
    Pieter Van Molle, Tim Verbelen, Bert Vankeirsbilck, Sofie Mylle, Evelien Verhaeghe, Lieve Brochez, Jonas De Vylder, Bart Diricx, Pieter Simoens, Bart Dhoedt (Belgium)
  • P001 - Genomic aberrations may predict positive sentinel lymph node biopsy in melanoma of young adults
    Sophia Ma, Karina Vivar, Vernon Sondak, Jane Messina (United States)
  • P002 - Stromal gene expression predicts sentinel lymph node metastasis of primary cutaneous melanoma
    Sindhuja Sominidi-Damodaran, Suzette Arias Mejias, Mark R Pittelkow, Julia S Lehman, Tina J Hieken, Martin H. van Vliet, Jvalini Dwarkasing, Domenico Bellomo, Alexander Meves (United States)
  • P006 - Development and validation of a nomogram to assess sentinel node biopsy positivity in melanoma patients
    Eduardo Bertolli, Vinicius Fernando Calsavara, Mariana Petaccia de Macedo, Clovis Antonio Lopes Pinto, João Pedreira Duprat Neto (Brazil)
  • P005 - Whole-body MRI including diffusion weighted imaging for the surveillance of melanoma patients at high risk for recurrence
    Yanina Jeanne Leona Jansen, Willekens inneke, Carola Brussaard, Bart Neyns (Belgium)
  • P008 - Clinical significance of braf/nras concurrent mutations in a clinic-based metastatic melanoma cohort
    Laura Del Regno, Baptiste Louveau, Barouyr Baroudjian, Aurelie Sadoux, Maxime Battistella, Julie Delyon, Nicole Basset Seguin, Celeste Lebbe, Samia Mourah, Fanelie Jouenne (France)
  • P010 - Molecular genetic testing of ocular melanoma (uveal and conjunctival melanoma)
    Valeriya Nazarova, Kristina Orlova, Mazurenko Natalia, Igor Utyashev, Lev Demidov (Russian Federation)
  • P007 - Epidemiological study of adjuvant treatments from the french national melanoma database RIC-MEL
    Emilie Varey, Stéphane Dalle, Thierry Lesimple, Henri Montaudié, Bernard Guillot, Laurent Mortier, Marie-Thérèse Leccia, François Skowron, Philippe Celerier, Nicolas Meyer, Amir Khammari, Céleste Lebbé, Brigitte Dreno (France)
  • P009 - MIR-193a as therapeutic agent in cutaneous melanoma
    Sara Carpi, Beatrice Polini, Antonella Romanini, Paola Nieri (Italy)
  • P011 - Response to chemotherapy after immunotherapy in 19 advanced melanoma patients
    Mélanie Saint-Jean, Clémentine Fronteau, Lucie Peuvrel *, Eugénie Clapeau, Anthony Sourisseau, Justine Daguzé, Louise Muguet, Amir Khammari, Emilie Varey, Gaëlle Quéreux, Brigitte Dréno (France)
  • P015 - Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases
    Pauline Tetu, Clara Allayous, Bastien Oriano, Stéphane Dalle, Laurent Mortier, Marie-Therese Leccia, Bernard Guillot, Sophie Dalac, Caroline Dutriaux, Jean-Philippe Lacour, Philippe Saiag, Florence Brunet-Possenti, Julie De Quatrebarbes, Pierre-Emmanuel Stoebner, Delphine Legoupil, Marie Beylot-Barry, Thierry Lesimple, François Aubin, Brigitte Dreno, Sameh Mohamed, Alice Ballon, Raphaël Porcher, Céleste Lebbé (France)
  • P012 - The importance of pharmacists for dabrafenib and trametinib use in real-life: analysis of data from pharmaceutical consultations since 2016
    Claire Davoine, François Cartier, Anne Toulemonde-Deldicque, Pauline Laly, Céleste Lebbé, Barouyr Baroudjian, Julie Delyon, Isabelle Madelain (France)
  • P013 - Severe gastrointestinal toxicity of MEK inhibitors: a 5-year monocentric experience
    Barouyr Baroudjian, Nadim Mourad, Nelson Lourenco, Julie Delyon, Pirayeh Eftekhari, Philippe Bertheau, Clara Allayous, Cécile Pagès, Mathieu Allez, Céleste Lebbé (France)
  • P014 - Immune-related hepatitis: clinical aspect and proposed management
    Marie-Léa Gauci, Barouyr Baroudjian, Ulysse Bédérède, Charlotte Zéboulon, Julie Delyon, Clara Allayous, Martine Bagot, Isabelle Madelaine, Matthieu Resche-Rigon, Nicolas Poté, Mohamed Bouattour, Olivier Roux, Céleste Lebbé (France)
  • P016 - Improving patient experience of immunotherapy treatment for melanoma: the leeds nurse-led immunotherapy telephone clinic
    Maria Marples, Helen Jackson, Helen Nicholson, Beverley Ryder, Karen Ingham, Jane Hook (United Kingdom)

What is new in NMSC biology?

Friday, April 26th 2019 | 17:00 - 18:00 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Irene LEIGH (United Kingdom), Dany NASSAR (France), Chrysalyne SCHMULTS (United States)

  • Mechanisms of Resistance to Hedgehog/Smoothened Inhibitors in BCC
    Michael MIGDEN (United States)
  • Regulation of Epithelial Mesenchymal Transition in SCC
    Dany NASSAR (France)
  • Squamous Carcinogenesis: Commonalities and Difference Across Epithelial Cell Types
    Catherine HARWOOD (United Kingdom)
  • Molecular Prediction of Recurrence and Metastasis in SCC
    Chrysalyne SCHMULTS (United States)

Genodermatoses and associated cancers

Friday, April 26th 2019 | 17:00 - 18:00 | ROOM 151 - Level 1

Chair : Susanna PUIG (Spain), Pierre VABRES (France), Pierre WOLKENSTEIN (France)

  • Genetics of basal cell carcinoma
    Sergey NIKOLAEV (France)
  • Genetics of familial melanoma
    Susanna PUIG (Spain)
  • Neurofibromatosis 1 and related tumours
    Pierre WOLKENSTEIN (France)
  • Genetic disorders of the PIK3CA/PTEN/MTOR pathway
    Pierre VABRES (France)

Free communications 3: Melanoma biomarkers, diagnostic

Friday, April 26th 2019 | 17:00 - 18:30 | PETIT AMPHITHEATRE - Level 0

Chair : Véronique BATAILLE (United Kingdom), Julie DELYON (France), Caroline GAUDY (France), Emmanuella GUENOVA (Switzerland)

  • FC22 - Clinical and dermoscopic features of thin nodular melanoma: a study of the international dermoscopy society
    A. Lallas, D. Sgouros, A. Zarras, A. Kyrgidis, G. Argenziano, I. Zalaudek, M. Pizzichetta, A. Marghoob, K. Liopyris, J. Malvehy, C. Oikonomou, R. Braun, A. Flórez Menedez, H. Cabo, G. Nazzaro, S. Lanssens, S. Menzies, J. Paoli, G. Kaminska-Winciorek, C. Longo, A. Katoulis, Z. Apalla, D. Ioannides, L. Thomas, I. Tromme, D. Ogata, C. Dessinioti, S. Puig, A. Scope, H. Kittler, A. J. Stratigos
  • FC23 - Computer-aided classifier with a deep convolutional neural network surpasses board-certified dermatologists in skin tumor diagnosis
    Yasuhiro Fujisawa, Yuzo Otomo, Yasunari Ogata, Yoshiyuki Nakamura, Manabu Fujimoto (Japan)
  • FC20 - MC1R gene variants and melanoma risk according to histological type, body site, and breslow thickness: a pooled analysis from the M-SKIP project
    Saverio Caini, Sara Gandini, Francesca Botta, Elena Tagliabue, Sara Raimondi, Eduardo Nagore, Ines Zanna, Patrick Maisonneuve, Julia Newton-Bishop, David Polsky, Rajiv Kumar, Peter A Kanetsky, Veronica Hoiom, Paola Ghiorzo, Maria Teresa Landi, Gloria Ribas, Chiara Menin, Alexander J Stratigos, Giuseppe Palmieri, Gabriella Guida, Jose Carlos García-Borrón, Hongmei Nan, Julian Little, Francesco Sera, Susana Puig, Maria Concetta Fargnoli (Italy)
  • FC26 - Multiple primary cutaneous melanoma: incidence, time to subsequent melanomas, differences in staging and survival
    Mary-Ann El Sharouni, Arjen Witkamp, Vigfús Sigurdsson, Paul van Diest (Netherlands)
  • FC24 - Sex differences in genetic modulation of melanoma-specific and disease-free survival
    Miriam Potrony, Neus Calbet-Llopart, Marc Combalia, Gemma Tell-Marti, Joan Anton Puig-Butille, Alicia Barreiro, Sebastian Podlipnik, Cristina Carrera, Josep Malvehy, Susana Puig (Spain)
  • FC30 - Clinicopathological factors associated with mortality of thin (≤1.00mm) cutaneous melanoma
    Magdalena Claeson, Peter Baade, Susan Brown, H Peter Soyer, B Mark Smithers, Adele C Green, David C Whiteman, Kiarash Khosrotehrani (Australia)
  • FC25 - Inhibition of EMMPRIN/VEGFR-2 interaction decreases malignant phenotype of melanoma models
    Alexandra Landras, Coralie Reger De Moura, Aurelie Sadoux, Bruno Villoutreix, Juan Fernandez- Recio, Maxime Battistella, Celeste Lebbe, Samia Mourah (France)
  • FC27 - Circulating PD-L1 expressing cytotoxic T cells are correlated with a negative immune climate and are prognostic in melanoma
    Annabel Meireson, Vibeke Kruse, Inès Chevolet, Nora Sundahl, Piet Ost, Lieve Brochez (Belgium)
  • FC28 - Ambra1 and loricrin; a paradigm shift in the prognostication and stratification of AJCC stage I melanoma
    Penny Lovat, Rob Ellis, Diana Tang, Batoul Nasr, Ashleigh McConnell, Joy Allen, Alison Greenwood, Paul Barrett, Edward Carling, Graeme Watson, Stuart Horswell, Dalvir Bajwa, Marie Labus (United Kingdom)
  • FC29 - A targeted mRNA analysis predicts survival of metastatic melanoma patients under braf inhibitors
    Baptiste Louveau, Julie Delyon, Coralie Reger De Moura, Maxime Battistella, Fanelie Jouenne, Aurelie Sadoux, Marie-Pierre Podgorniak, Oren Marco, Julie Caramel, Stephane Dalle, Nicolas Dumaz, Celeste Lebbe, Samia Mourah (France)
Saturday, April 27th 2019

Dermoscopy and confocal microscopy cases 1

Saturday, April 27th 2019 | 08:30 - 09:30 | ROOM 151 - Level 1

Chair : Philippe BAHADORAN (France), Josep MALVEHY (Spain), Dimitris SGOUROS (Greece)

  • equivocal hypomelanotic lesion or regressive lesion (melanoma vs nevus); Difficult BCC; Lichen planus like keratosis simulating melanoma in dermoscopy
    Caterina LONGO (Italy)
  • vulvar melanosis vs MM; Nail melanonychia (melanoma vs benign lesion); melanoma during vemurafenib or immunotherapy treatment
    Mona AMINI-ADLER (France)
  • basal cell carcinoma (dermoscopy, OCT and confocal), squamous cell carcinoma (Bowen), melanoma vs nevus
    Mariano SUPPA (Belgium)
  • early LMM (diagnosis, margins, management, recurrences,..); Benign equivocal flat pigmented lesion on the face; Case of ex-vivo confocal in Mohs surgery (multimodal)
    Susanna PUIG (Spain)

Cases: management of difficult to treat carcinomas

Saturday, April 27th 2019 | 08:30 - 11:00 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Jean-Jacques GROB (France), Eve MAUBEC (France), Chrysalyne SCHMULTS (United States), Victor FARRICHA (Portugal)

  • Advanced SCC arising in hidradenitis suppurativa
    Eve MAUBEC (France)
  • Multiple scalp SCCs in a patient with chronic lymphocytic leukemia
    Chrysalyne SCHMULTS (United States)
  • Rapid growth of SCC while on JAK inhibitor for myelofibrosis
    Victor FARRICHA (Portugal)
  • What is a difficult to treat BCC?”
    Jean-Jacques GROB (France)
  • A young patient with sarcoidosis and voriconazole-induced locally advanced SCC
    Eve MAUBEC (France)
  • A renal transplant patient with multiply recurrent SCC. Is anti PD-1 treatment ever appropriate in transplant patients?
    Chrysalyne SCHMULTS (United States)

Dermoscopy and confocal microscopy cases 2

Saturday, April 27th 2019 | 09:30 - 10:30 | ROOM 151 - Level 1

Chair : Harald KITTLER (Austria), Aimilios LALLAS (Greece), Iris ZALAUDEK (Austria)

  • When dermoscopy is straight forward
    Aimilios LALLAS (Greece)
  • When dermoscopy is not straight forward
    Harald KITTLER (Austria)
  • When confocal is of help
    Caterina LONGO (Italy)
  • Pre- and intra-operative use of non-invasive techniques
    Susanna PUIG (Spain)

Keynote lectures 4

Saturday, April 27th 2019 | 11:30 - 12:30 | AMPHITHEATRE LAVOISIER - Level 1

Chair : Céleste LEBBE (France), Véronique DEL MARMOL (Belgium)

  • What's new in non melanoma skin cancer?
    Brigitte DRENO (France)
  • What's new in melanoma?
    Olivier MICHIELIN (Switzerland)
  • What's new in cutaneous lymphoma?
    Marie BEYLOT-BARRY (France)

Closing Ceremony & Awards

Saturday, April 27th 2019 | 12:30 - 13:00 | AMPHITHEATRE LAVOISIER - Level 1

The awards of 500€ each plus a certificate will go to the top 2 Oral Communications and the top 3 E-Posters. The prize-winning abstracts will be selected by members of the Local Scientific Committee.

By continuing to browse this website, you accept cookies which are used to offer a personalized experience on our website, generate statistics and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Ok Read more